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ABSTRACT
OBJECTIVES: The National Patient-Centered Clinical Re-
search Network (PCORnet) supports observational and clinical
research using health care data. The PCORnet Antibiotics and
Childhood Growth Study is one of PCORnet’s inaugural obser-
vational studies. We sought to describe the processes used to
integrate and analyze data from children across 35 participat-
ing institutions, the cohort characteristics, and prevalence of
antibiotic use.
METHODS: We included children in the cohort if they had at least
one same-day height and weight measured in each of 3 age
periods: 1) before 12 months, 2) 12 to 30 months, and 3) after
24 months. We distributed statistical queries that each institu-
tion ran on its local version of the PCORnet Common Data Model,
with aggregate data returned for analysis. We defined over-
weight or obesity as age- and sex-specific body mass index ≥85th
percentile, obesity ≥95th percentile, and severe obesity ≥120%
of the 95th percentile.
RESULTS: A total of 681,739 children met the cohort inclu-
sion criteria, and participants were racially/ethnically diverse
(24.9% black, 17.5% Hispanic). Before 24 months of age, 55.2%
of children received at least one antibiotic prescription; 21.3%
received a single antibiotic prescription; 14.3% received 4 or more;
and 33.3% received a broad-spectrum antibiotic. Overweight and
obesity prevalence was 27.6% at age 4 to <6 years (n = 362,044)
and 36.2% at 9 to <11 years (n = 58,344).
CONCLUSIONS: The PCORnet Antibiotics and Childhood Growth
Study is a large national longitudinal observational study in a
diverse population that will examine the relationship between early
antibiotic use and subsequent growth patterns in children.
KEYWORDS: antibiotics; body mass index; childhood growth;
childhood obesity; electronic health records; research infrastructure
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The widespread availability of health care data
through electronic health records (EHRs) and other data
sources provide unique opportunities to conduct pragmatic
clinical trials and observational studies on a large scale. The
National Patient-Centered Clinical Research Network
(PCORnet) is a distributed research network that uses health
care data to facilitate multisite clinical trials and observational
research studies.1–3 PCORnet has 13 clinical data research
WHAT’S NEW
The National Patient-Centered Clinical Research Network
(PCORnet) provides an unprecedented opportunity to
conduct research using health care data. In 35 health care
institutions, we assembled a large cohort to examine an-
tibiotics and childhood growth. More than half of children
received an antibiotic prescription before 2 years of age.
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networks (CDRNs) that contribute health information for
over 128 million patients. Within the CDRNs, data are or-
ganized in a Common Data Model (CDM) that allows for
standardization across institutions and the development of
efficient and reusable tools to capture and analyze data.4
This type of data infrastructure is essential for patient-
centered research that requires large sample sizes, such as
studies of rare diseases or studies that require assessments
of heterogeneity of treatment effects, with various types of
exposures among specific subgroups. To help develop in-
frastructure for observational research in PCORnet, the
Patient-Centered Outcomes Research Institute (PCORI)
funded 2 initial observational studies to explore diverse re-
search questions and launch PCORnet into a research-
ready data system.3,5 One of these studies, the PCORnet
Antibiotics and Childhood Growth Study, was the first effort
in PCORnet to establish a large pediatric cohort across the
network, and the first study in PCORnet to actively char-
acterize prescribing data. Having access to a large pediatric
cohort also will enable assessments of different types, timing,
and doses of antibiotics on weight outcomes, which has been
difficult to do with smaller studies.
Our objective was to evaluate the utility of this cohort for
conducting comparative effectiveness research on medica-
tions and growth in young children. Here we describe the
processes used to integrate, synchronize, and analyze data
from children across 35 health care institutions organized
in 10 CDRNs, and we describe the cohort characteristics,
including antibiotic use before 24 months of age and preva-
lence of overweight and obesity from early to midchildhood.
METHODS
PARTICIPATING INSTITUTIONS AND THE PCORNET CDM
PCORI, created by the Affordable Care Act of 2010, is
a funding agency that supports patient-centered compara-
tive effectiveness research within 5 priority areas: “evaluating
prevention, diagnosis, and treatment options; improving health
systems; enhancing communication and dissemination of evi-
dence; addressing disparities in health and health care; and
improving comparative effectiveness research methods and
data infrastructure.”6 PCORI created PCORnet to expand the
data infrastructure available for comparative effectiveness
research in a manner that incorporates the input of
stakeholders.2 In addition to the 13 participating CDRNs in-
cluding data from nearly 100 health care systems, PCORnet
has 20 Patient-Powered Research Networks that are focused
on specific diseases or populations (contributing to both stake-
holder engagement efforts and data) and 2 Health Plan
Research Networks that are working to link health insur-
ance claims data to PCORnet EHR data.
In PCORnet, data are organized by Network Partners.
These Network Partners include data from either one con-
tributing health care institution or, in the case of centralized
Network Partners, from multiple institutions. In this study,
28 Network Partners participated, and these partners held
data for 35 institutions across 10 CDRNs, including inte-
grated delivery systems, freestanding children’s hospitals,
and federally qualified health centers (Supplemental Table 1).
To participate in the study, Network Partners had to meet
data quality standards that were set forth by the PCORnet
Coordinating Center. These included assessments of data
model conformance, missing data in required tables and vari-
ables, and data plausibility in date and vital measure fields.7
Required tables included enrollment, encounters, demo-
graphics, vital findings, diagnoses, and procedures. The study
team additionally required that Network Partners had the
capacity to create a pediatric cohort that met the study’s in-
clusion criteria and that could identify antibiotic prescriptions.
Of the 44 institutions initially planned for inclusion, we
removed 8 from the study for the following reasons: did not
meet Coordinating Center data quality standards (n = 1) or
did not meet them by February 1, 2017 (n = 1); did not have
access to outpatient prescription medications in their CDM
(n = 2); were unable to map their prescribing data to RxNorm
codes needed for the study by February 1, 2017 (n = 1); were
unwilling to share individual-level data (n = 2); or chose not
to participate because the site had a small pediatric popu-
lation available in their CDM (n = 1). A team of stakeholders
from participating CDRNs and 2 of the Patient-Powered Re-
search Networks, including parents, providers, health system
representatives, and patient advocates, closely informed the
study conception and design, and provided ongoing feed-
back throughout the study.
The PCORnet CDM consists of 15 tables and over 100
variables available for research.4 An in-depth assessment of
data usability and consistency was necessary before con-
ducting statistical analyses, a process called study-specific
data characterization. For the PCORnet Antibiotics and Child-
hood Growth Study, this process included capturing site-
level aggregate data on study-specific variables (eg,
demographics, diagnoses, medications, vital signs). The study
team analyzed this data to determine which sites met data
quality eligibility requirements, while providing initial in-
formation on the cohort of interest.
DISTRIBUTED STATISTICAL NETWORK QUERIES
Sites extract data from their local EHR systems and other
health care data repositories, such as insurance claims, and
transform those data to meet CDM standards. The PCORnet
distributed research network model addresses governance
and privacy concerns by allowing institutions to maintain
data locally, rather than create a network-wide centralized
database. Queries written to conform to the CDM stan-
dards are distributed to Network Partners for local execution,
resulting in the return of standardized output that can be ag-
gregated with other partners. To produce statistical query
packages for distribution, either for data characterization or
study analyses, PCORnet follows a standard workflow,
informed by the setup of the US Food and Drug Adminis-
tration’s Sentinel program.8 The Sentinel program utilizes
claims data from health insurers to examine drug safety across
the United States. The workflow begins with the develop-
ment of scientific specifications that describe the purpose
of the query and the intended analyses, which serves as a
blueprint for the programming team. The programmers then
develop a SAS statistical query to capture relevant data from
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Network Partners or to conduct analyses (SAS Institute, Cary,
NC). Study teams are also responsible for generating and
reviewing codes for relevant variables used for the query.
This study used International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM), and SNOMED-
CT codes for diagnoses, and RxNorm and National Drug
Code (NDC) codes for medications.
After query program development has been completed and
tested with simulated data at the PCORnet Coordinating
Center and at sites for beta testing, the program is distrib-
uted to the network via the PopMedNet Query Tool.9 Once
results are returned from all responding sites, responses are
collapsed into a single summary report for review and analy-
sis by the study team (Supplemental Fig. 1) in the case of
aggregated data, and into analytic files for other types of
data, such as patient-level data.
STUDY COHORT
The PCORnet Antibiotics and Childhood Growth study
cohort included children from birth to <11 years of age. In-
clusion criteria were one or more encounters with same-
day length/height and weight measured in each of the
following intervals: 0 to 12 months, 12 to < 30 months, and
24+ months of age. The latter 2 age periods overlapped to
allow for the possibility that children had their 2-year-old
well-child visit soon after their second birthday. Thus, chil-
dren with only 2 measures were eligible for inclusion if the
second was between 24 and 30 months of age. Less than
1% of the children met the cohort criteria with only 2 mea-
sures. Children were excluded from the cohort if they did
not have a male or female designation for sex. Most Network
Partners had data available from 2009 or 2010 until mid-
to late 2016, with a few exceptions. Only one had data that
began before 2000; another Network Partner’s data avail-
ability ended in 2015.
VARIABLES AND DATA ANALYSIS
All data presented here were from descriptive analyses
of all participating institutions. We presented some descrip-
tive data anonymously at the Network Partner level for those
23 Network Partners that had at least 5000 children in the
cohort. Demographics were defined according to the
PCORnet CDM standards. Drug codes for antibiotics were
identified using a two-pronged approach. First, we cap-
tured NDC codes for antibiotics using the functional
classification system from First Databank.10 Crosswalks avail-
able from the National Library of Medicine were used to
convert the NDC code list into RxNorm codes,11 the pre-
scription classification system used for this study. Second,
to identify additional systemic antibiotic codes in RxNorm,
we separately captured RxNorm semantic clinical drug form
(SCDF) terms using the Anatomic Therapeutic Classifica-
tion system.12 Under the RxNorm hierarchy, we also collected
all less specific codes that were related to the SCDF terms
to maximize capture of antibiotics; these included drug com-
ponent, ingredient, brand name, multi-ingredient, and precise
ingredient codes. We further captured more specific codes
related to the SCDF terms, including semantic clinical drug
or pack and semantic branded drug or pack codes. During
manual review of these lists, we excluded antiprotozoal medi-
cations, antibiotics not available in the United States,
veterinary medicines, and most intravenous medications. This
led to a final antibiotic list of oral medications and intra-
venous or intramuscular ceftriaxone and penicillin,
medications likely to be prescribed in the outpatient or emer-
gency department setting. This restriction ensured consistency
across the network—several did not have inpatient
medications—and allowed this study to focus on antibiot-
ics whose use we believed could be potentially more
modifiable than most intravenous medications.
Network Partners did not routinely have days supplied
available for prescriptions. Thus, we defined exposure to an-
tibiotics by the number of episodes of antibiotics prescribed.
The time window for an antibiotic episode was 7 days, such
that any antibiotic prescriptions within a 7-day period of
another prescription were joined together into a single
episode. Narrow-spectrum antibiotics included amoxicillin,
penicillin, and dicloxacillin; broad-spectrum antibiotics in-
cluded all others, including penicillin combinations, such
as amoxicillin/clavulanic acid. To define whether the episode
was for a broad- or narrow-spectrum antibiotic, we used the
highest spectrum antibiotic prescribed within the episode.
Diagnostic codes were identified for potential confound-
ers or effect modifiers, such as asthma and prematurity, as
well as diagnoses for chronic conditions. For complex chronic
conditions, we used the list of ICD-9-CM code clusters de-
veloped by Feudtner et al.13 Using these diagnoses, we added
to the list by searching an Optum database to ensure that
we captured all relevant codes for these diagnoses. For those
sites that used only SNOMED-CT codes for diagnoses, we
translated the final ICD-9-CM code list to SNOMED-CT
using an established crosswalk.14
Computation of body mass index (BMI) z scores uti-
lized the World Health Organization (WHO) growth standards
for children <24 months of age: underweight if age- and sex-
specific BMI was <2.3rd percentile, normal weight if 2.3rd
to <97.7th percentile, and overweight/obesity if ≥97.7th
percentile.15 We used the US Centers for Disease Control
and Prevention National Health and Nutrition Examina-
tion Survey (NHANES) 2000 growth charts to classify weight
status of children ≥24 months of age: underweight if <5th
percentile, normal weight 5th to <85th, overweight 85th to
<95th percentile, obesity ≥95th percentile, and severe obesity
≥120% of the 95th percentile.16 We removed implausible
values of BMI z scores less than −5 and greater than 8, ac-
counting for the recommended bounds for both the WHO
(−5, +5) and Centers for Disease Control and Prevention (−4,
+8). We utilized a SAS-based summary program to aggre-
gate data across responding Network Partners and format
into a readable Excel (Microsoft, Redmond, Wash) report
for analyses and characterization.
RESULTS
The final study cohort included 681,739 children, which
was 38% of all children who had at least one same-day
height/weight measurement at <12 months of age and 71%
of children who also had at least one additional same-day
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height and weight measurement at 12 to <30 months of age
(Supplemental Fig. 2). Slightly more than half were boys
(52.3%), and the cohort was racially diverse, with 53.4%
white, 24.9% black or African American, 5.9% other race,
and 4.2% Asian (Table 1). Although there were substantial
missing data on Hispanic ethnicity, 17.5% of the cohort
was identified as Hispanic. All 28 Network Partners
contributed to the cohort; the largest CDRN contributors were
PEDSnet (46% of the cohort), PORTAL (22%), ADVANCE
(9%), and Mid-South (8%).
Birth-related diagnoses were rarely documented in the
EHRs, except for prematurity, with 7.7% of children having
a code for prematurity (Table 1). By comparison, the preva-
lence of US preterm births in 2014 was 9.5%.17 Because
several of the participating health systems were referral
centers, the rate of chronic conditions was high, including
13.8% who had at least one diagnostic code documented
for asthma, and 6.9%, 6.2%, and 3.1% for cardiovascular,
other defects (mostly congenital defects), and respiratory di-
agnoses, respectively, at <5 years of age.
Among all children in the cohort, 55.2% received at least
one prescription for an antibiotic at <24 months of age
(Table 2). Among the 23 Network Partners with at least 5000
children in the cohort, the fraction of children prescribed
at least one antibiotic ranged from 19% to 77%; 16 of the
23 Network Partners, including most of the larger ones, had
prescribing rates above 50% (Fig. 1A). For all children in
the cohort, 21.3% had 1 prescription episode and 14.3% had
4+ prescription episodes <24 months (Table 2).
Narrow-spectrum antibiotics—nearly all amoxicillin—
were more commonly prescribed, with 43.0% of all children
in the cohort (over three quarters of children who received
any antibiotics) receiving at least one prescription for a
narrow-spectrum antibiotic at <24 months of age and 33.3%
receiving at least one broad-spectrum antibiotic (Table 2).
Across the 23 Network Partners with at least 5000 chil-
dren, 16 had higher rates of prescribing for narrow-spectrum
antibiotics (Fig. 1B).
Nearly a quarter of children (23.4%) received 1 narrow-
spectrum antibiotic, and 3.4% received 4+ compared to 16.8%
and 5.9% for broad-spectrum antibiotics (Table 2).
Amoxicillin/clavulanic acid and azithromycin were pre-
scribed at least once for 14.3% and 9.2% of children,
respectively.
Mean BMI z score was −0.30 (WHO, SD 1.31) at 0 to
<6 months of age, rising to 0.59 (NHANES, SD 1.18) at 9
to 11 years of age (Supplemental Table 2). The prevalence
of overweight and obesity across age groups was 3.7% among
0- to 6-month-olds, 27.6% among 4- to <6-year-olds, and
36.2% among 9- to <11-year-olds (Fig. 2, Supplemental
Tables 3 and 4). The prevalence of severe obesity was 2.5%
and 6.8%, respectively, for 4- to <6-year-olds and 9- to <11-
year-olds. There was a range in prevalence of overweight







Black, African American 170,007 (24.9%)
Asian 28,356 (4.2%)
Multiple race 14,184 (2.1%)
Native Hawaiian, other Pacific Islander 2,930 (0.4%)
American Indian, Alaska Native 2,862 (0.4%)
Other 39,885 (5.9%)





Refused/unknown/no information 114,660 (16.8%)
Birth-related diagnoses
Prematurity 52,752 (7.7%)
Heavy for gestational age newborn 9,907 (1.5%)












Malignant neoplasms 6,593 (1.0%)
Gastrointestinal 6,015 (0.9%)
Table 2. Exposure to Antibiotics and Other Medications Before Age
2 Years
Antibiotics n (%)
No antibiotics 305,489 (44.8%)
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and obesity across the 23 Network Partners with at least 5000
children in the cohort (Supplemental Fig. 3). For example,
prevalence of obesity among 4- to 6-year-olds had a range
of 5% to 22%.
DISCUSSION
Using the PCORnet data network infrastructure, we as-
sembled a study cohort of 681,739 children with multiple
measures of height and weight captured in EHRs across 35
health care institutions. More than half of these children had
height and weight data at ages 4 to <6 years and 9% at ages
9 to <11 years. The cohort has broad diversity in geogra-
phy, demographics, and care settings, and provides a rich
data source for the longitudinal study of childhood growth.
PCORnet’s architecture strikes a balance between facili-
tating large-scale collaborative research and managing
institutional risks. The PCORnet Antibiotics and Child-
hood Growth Study, engaging 28 (34%) of 82 Network
Partners, provides an early test of the network, including
valuable information about network governance and opera-
tions, patient engagement, use of prescribing and
anthropometric data, and population characteristics. Most
contributing health care institutions in the network are an-
chored by large hospitals in urban or suburban areas, which
may explain the high rates of complex chronic conditions.
Overall, however, the clinical data collected align well with
expectations for pediatric populations.
Results from this descriptive study demonstrate that
PCORnet is well suited for pediatrics observational epide-
miologic research, with the capacity to create large cohorts
for the study of health care exposures and outcomes.
PCORnet can also provide meaningful national surveil-
lance data on health care utilization and outcomes. In this
cohort, over half of included children received at least one
prescription for antibiotics by their second birthday. While
recommended first-line antibiotics were most common, one
third of children received at least one broad-spectrum an-
tibiotic, and 1 in 7 received 4+ courses. This results in a
significant exposed group for both antibiotics overall and
for subset analyses by type and extent of exposure. The rate
of antibiotic exposure is comparable to prior studies.18–20
Anthropometric measures for this cohort are similar to
national survey estimates. For most age categories, the median
BMI z score is slightly positive. Prevalence of obesity in our
cohort was 13.1% from ages 4 to <6 years and 20.0% from
Figure 1. PCORnet Antibiotics and Childhood Growth Study, prescribing rate and breakdown of antibiotic spectrum by Network Partner.
Shown is the percentage of children who received an antibiotic prescription before 24 months of age overall for the cohort and by Network
Partner for those contributing at least 5000 children to the cohort (A) and the percentage of children receiving any narrow- and broad-
spectrum antibiotic before 24 months of age overall and by Network Partner (B). Denominator for (A) includes all children in the cohort
and for (B) includes all children who received at least one antibiotic prescription before 24 months of age. Among the 23 Network Part-
ners presented, 16 had antibiotic prescribing rates of >50% and had higher narrow-spectrum antibiotic prescribing rates than broad. PCORnet
indicates National Patient-Centered Clinical Research Network.
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ages 9 to <11 years, compared to 9% among 2- to <6-year-
olds and 18% among 6- to <12-year-olds in NHANES data
spanning 2011 to 2014.21 Prevalence of severe obesity was
2.5% for 4- to <6-year-olds and 6.8% for 9- to <11-year-
olds, compared to 1.7% for 2- to <6-year-olds and 4.3% for
6- to <12-year-olds in NHANES 2011–2014. The slightly
higher prevalence in our cohort may reflect differences in
age ranges, given the higher prevalence of childhood obesity
as age increases or differences in patient mix between those
children continuously enrolled in PCORnet health systems
versus the US population.21,22 It may also reflect character-
istics of the cohort, which includes a larger proportion of
African American children and children living in urban set-
tings than the US population.21
The objective of the PCORnet Antibiotics and Child-
hood Growth Study is to better characterize the relationship
between antibiotics and childhood obesity in the United
States. This study is powered to examine multiple poten-
tial associations of antibiotics and weight, including the
effects of types, timing, and frequency of antibiotic use in
the first 2 years of life on BMI, obesity, and growth. Quan-
tifying the precise effect size of this association will provide
pertinent information to patients and clinicians regarding po-
tential obesogenic risks of antibiotic prescriptions. Compared
to prior studies that have examined the relationship between
antibiotic use and growth in children, this cohort provides
the largest and most diverse population for study. Prior reports
have included single health system or single region studies
in the United States, including children in Northern Cali-
fornia (260,556 children) or central Pennsylvania (142,824
children), as well as smaller European national studies such
as in England (11,532 children) or Denmark (28,354
children).23–26 Representation of African American chil-
dren in this cohort is higher than the entire US population
(25% vs 12%); the proportion of patients identifying as His-
panic is similar to the US population. This cohort
demonstrates a modest overrepresentation of several chronic
conditions, which may be due to the inclusion of several large
health systems providing tertiary care. Also, the preva-
lence of chronic disease could have been higher solely
Figure 2. PCORnet Antibiotics and Childhood Growth Study, cohort weight class. Study calculated age- and sex- specific BMI (BMI z
score) for children at each age period. World Health Organization growth standards for children were utilized before 24 months of age:
underweight if BMI z score was <2.3rd percentile, normal weight if 2.3rd to <97.7th percentile, and overweight/obesity if ≥97.7th percen-
tile (A). CDC NHANES 2000 growth charts for children were utilized for children aged 2 to 10.9 years: underweight if BMI z score <5th
percentile, normal weight 5th to <85th percentile, overweight 85th to <95th percentile, obesity ≥95th percentile, and severe obesity ≥120%
of 95th percentile (B). Rates of overweight, obesity, and severe obesity were higher for older children. BMI indicates body mass index;
CDC, US Centers for Disease Control and Prevention; NHANES, National Health and Nutrition Examination Survey; and PCORnet, Na-
tional Patient-Centered Clinical Research Network.
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because the cohort includes children who have received health
care services.
In addition to the overrepresentation of urban environ-
ments and chronic conditions, it is important to note several
other limitations. Most significantly, available data did not
include other variables that influence the risk of childhood
obesity, including maternal health or gestational factors, as
well as environmental, social, behavioral, and dietary factors.
The PCORnet study will address the absence of gesta-
tional data by linking maternal and child health records for
a subset of the cohort, allowing inclusion of maternal BMI,
child birth weight, and maternal weight gain. Another limi-
tation was that antibiotic exposure was measured using
prescribing records, which may overestimate exposure in
cases where children do not complete prescribed courses of
antibiotics. Prescribing records also may underestimate ex-
posure because some prescribing may occur in health care
settings not covered by a contributing institution and would
therefore be missed. Similarly, our identification of chronic
conditions relies on one or more occurrences of diagnosis
codes recorded during clinical encounters and may overes-
timate prevalence due to use of these codes to rule out
diagnoses. When we capture and analyze individual-level
data on participants, rather than aggregate data only (as used
herein), we will be able to compensate for this by requir-
ing repeated presence of codes, consistent with the chronic
nature of the conditions.
More generally, the use of routine clinical data for the
study may result in missingness (eg, patients with race or
Hispanic ethnicity not recorded), misestimation (eg, higher
use of diagnostic codes when ruling out conditions), or loss
of detail (eg, use of ICD-9-CM in billing data, losing speci-
ficity of diagnoses primarily recorded in the EHR). These
limitations are common to studies using EHR and admin-
istrative data.
CONCLUSIONS
The PCORnet Antibiotics and Childhood Growth cohort
demonstrates the capacity of PCORnet to facilitate capture
of data on large pediatric populations for research, includ-
ing early childhood growth, chronic conditions, infectious
diagnoses, and antibiotic usage. This study provides valu-
able surveillance information on antibiotic utilization and
weight, and it is the largest study to date to examine the re-
lationship between antibiotic use in early life on weight
outcomes in childhood. The large sample size and detailed
clinical data will allow us to examine relationships among
the type, timing, and level of antibiotic exposure to deter-
mine whether these factors are related to weight outcomes.
PCORnet can provide significant opportunities to explore
precise research inquiries in pediatrics.
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